Lv58
980 积分 2024-01-30 加入
HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial
8小时前
已完结
Targeted protein degradation: from mechanisms to clinic
3天前
已完结
Molecular glue degraders: exciting opportunities for novel drug discovery
3天前
已完结
Amylin: Pharmacology, Physiology, and Clinical Potential
6天前
已完结
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
6天前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
7天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
7天前
已完结
A structural basis for amylin receptor phenotype
7天前
已完结
Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights
19天前
已完结
Oral PCSK9 Inhibitors: Can Novel Therapies Overcome Barriers to Effective LDL Cholesterol Management?
1个月前
已完结
皖公网安备34019202002308
